Clinical trial · Observational
The Favorable Impact of HBcAb Positive Grafts on Liver Transplantation for HBV-related HCC
The Favorable Impact of Hepatitis B Core Antibody Positive Grafts on Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma: a Nationwide Multicenter Retrospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The utilization of marginal grafts may help alleviate the demand mismatch. However, strategies to optimize the use of hepatitis B core antibody (HBcAb) positive grafts still requires further investigation. This study aims to investigate possible interactions between HBcAb positive grafts, HCC and HBV-related diseases, and long-term patient and graft survival. The study retrospectively analyzed patients undergoing liver transplantation in 8 centers between January 2015 and December 2020.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Transplantation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Interventions | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- HBcAb negative group
- description
- Liver transplant recipients with HBcAb negative grafts
- interventionNames
- Other: No Interventions
- label
- HBcAb positive group
- description
- Liver transplant recipients with HBcAb positive grafts
- interventionNames
- Other: No Interventions
Primary outcomes (1)
- measure
- Postoperative death
- timeFrame
- 2015.1.1-2023.12.31
- description
- The death of a patient following liver transplanation
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * (1) primary transplantation; (2) complete baseline data. Exclusion Criteria: * (1) re-transplantation, combined organ transplantation or living donor liver transplantation; (2) intrahepatic cholangiocarcinoma or combined hepatocellular-cholangiocarcinoma; (3) HBsAg positive graft; and (4) missing of baseline data. Patients who were lost to follow-up were also excluded.
References
Publications (0)
Data not yet available